Cargando…
Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
BACKGROUND: Oestrogens usually stimulate the progression of oestrogen receptor (ER)-positive breast cancer. Paradoxically, high-dose oestrogens suppress the growth of these tumours in certain circumstances. METHODS: We prospectively examined the efficacy and safety of ethinylestradiol treatment (3 m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777011/ https://www.ncbi.nlm.nih.gov/pubmed/24002591 http://dx.doi.org/10.1038/bjc.2013.520 |
_version_ | 1782284926988582912 |
---|---|
author | Iwase, H Yamamoto, Y Yamamoto-Ibusuki, M Murakami, K-I Okumura, Y Tomita, S Inao, T Honda, Y Omoto, Y Iyama, K-I |
author_facet | Iwase, H Yamamoto, Y Yamamoto-Ibusuki, M Murakami, K-I Okumura, Y Tomita, S Inao, T Honda, Y Omoto, Y Iyama, K-I |
author_sort | Iwase, H |
collection | PubMed |
description | BACKGROUND: Oestrogens usually stimulate the progression of oestrogen receptor (ER)-positive breast cancer. Paradoxically, high-dose oestrogens suppress the growth of these tumours in certain circumstances. METHODS: We prospectively examined the efficacy and safety of ethinylestradiol treatment (3 mg per day oral) in postmenopausal patients with advanced or recurrent ER-positive breast cancer who had previously received endocrine therapies, especially those with resistance to aromatase inhibitors. RESULTS: Eighteen patients were enrolled with the median age of 63 years and the mean observation time of 9.2 months. Three cases withdrew within 1 week due to oestrogen flare reactions with nausea, fatigue and muscle-skeletal pain. The response rate was 50% (9 out of 18), and the clinical benefit rate was 56% (10 out of 18). The stable disease (<6 months) was 17% (3 out of 18) and another 2 cases were judged as progressive disease. Time-to-treatment failure including 2 on treatment was a median of 5.6 months (range 0.1 to 14.5(+)). Although vaginal bleeding or endometrial thickening was observed in patients receiving long-term treatment, there were no severe adverse events, such as deep venous thrombosis or other malignancies. CONCLUSION: Although the mechanism of this treatment has not been fully understood, our data may contribute to change the common view of late-stage endocrine therapy. |
format | Online Article Text |
id | pubmed-3777011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-37770112014-09-17 Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study Iwase, H Yamamoto, Y Yamamoto-Ibusuki, M Murakami, K-I Okumura, Y Tomita, S Inao, T Honda, Y Omoto, Y Iyama, K-I Br J Cancer Clinical Study BACKGROUND: Oestrogens usually stimulate the progression of oestrogen receptor (ER)-positive breast cancer. Paradoxically, high-dose oestrogens suppress the growth of these tumours in certain circumstances. METHODS: We prospectively examined the efficacy and safety of ethinylestradiol treatment (3 mg per day oral) in postmenopausal patients with advanced or recurrent ER-positive breast cancer who had previously received endocrine therapies, especially those with resistance to aromatase inhibitors. RESULTS: Eighteen patients were enrolled with the median age of 63 years and the mean observation time of 9.2 months. Three cases withdrew within 1 week due to oestrogen flare reactions with nausea, fatigue and muscle-skeletal pain. The response rate was 50% (9 out of 18), and the clinical benefit rate was 56% (10 out of 18). The stable disease (<6 months) was 17% (3 out of 18) and another 2 cases were judged as progressive disease. Time-to-treatment failure including 2 on treatment was a median of 5.6 months (range 0.1 to 14.5(+)). Although vaginal bleeding or endometrial thickening was observed in patients receiving long-term treatment, there were no severe adverse events, such as deep venous thrombosis or other malignancies. CONCLUSION: Although the mechanism of this treatment has not been fully understood, our data may contribute to change the common view of late-stage endocrine therapy. Nature Publishing Group 2013-09-17 2013-09-03 /pmc/articles/PMC3777011/ /pubmed/24002591 http://dx.doi.org/10.1038/bjc.2013.520 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Iwase, H Yamamoto, Y Yamamoto-Ibusuki, M Murakami, K-I Okumura, Y Tomita, S Inao, T Honda, Y Omoto, Y Iyama, K-I Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
title | Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
title_full | Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
title_fullStr | Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
title_full_unstemmed | Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
title_short | Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
title_sort | ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777011/ https://www.ncbi.nlm.nih.gov/pubmed/24002591 http://dx.doi.org/10.1038/bjc.2013.520 |
work_keys_str_mv | AT iwaseh ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT yamamotoy ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT yamamotoibusukim ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT murakamiki ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT okumuray ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT tomitas ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT inaot ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT honday ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT omotoy ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy AT iyamaki ethinylestradiolisbeneficialforpostmenopausalpatientswithheavilypretreatedmetastaticbreastcancerafterprioraromataseinhibitortreatmentaprospectivestudy |